Insulin access and affordability in the USA: anticipating the first interchangeable insulin product

Lancet Diabetes Endocrinol. 2020 May;8(5):360-362. doi: 10.1016/S2213-8587(20)30105-4. Epub 2020 Mar 20.

Authors

Jing Luo¹, Aaron S Kesselheim², Ameet Sarpatwari²

Affiliations

¹ Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Electronic address: luoj@pitt.edu.
² Program on Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 32203681
DOI: 10.1016/S2213-8587(20)30105-4

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Biosimilar Pharmaceuticals / therapeutic use
Costs and Cost Analysis
Drug Costs*
Drugs, Generic / therapeutic use
Health Services Accessibility*
Humans
Insulin / economics*
Insulin / therapeutic use
United States

Substances

Biosimilar Pharmaceuticals
Drugs, Generic
Insulin

Grant support

KL2 TR001856/TR/NCATS NIH HHS/United States